Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ipratropium bromide HFA.

Keri Wellington1

  • 1Adis International Inc., Yardley, Pennsylvania 19067, USA. demail@adis.com

Treatments in Respiratory Medicine
|July 1, 2005
PubMed
Summary
This summary is machine-generated.

The new hydrofluoroalkane (HFA) propelled ipratropium bromide inhaler shows efficacy and tolerability comparable to older chlorofluorocarbon (CFC) inhalers for COPD patients. This HFA formulation offers a safe alternative for managing bronchospasm in chronic obstructive pulmonary disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris.

Drugs·2007
Same author

Spotlight on bicalutamide 150mg in the treatment of locally advanced prostate cancer.

Drugs & aging·2007
Same author

Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer.

Drugs·2006
Same author

Insulin glulisine.

Drugs·2006
Same author

Modified-release nifedipine: a review of the use of modified-release formulations in the treatment of hypertension and angina pectoris.

Drugs·2006
Same author

0.4% nitroglycerin ointment : in the treatment of chronic anal fissure pain.

Drugs·2006
Same journal

Comparative efficacy and tolerability of pholcodine and dextromethorphan in the management of patients with acute, non-productive cough : a randomized, double-blind, multicenter study.

Treatments in respiratory medicine·2006
Same journal

In Vitro Comparison of Output and Particle Size Distribution of Budesonide from Metered-Dose Inhaler with Three Spacer Devices during Pediatric Tidal Breathing.

Treatments in respiratory medicine·2006
Same journal

A Cross-Sectional Comparison of Direct Medical Care Costs among COPD and Asthma Patients Living in the Community in Northern Ireland.

Treatments in respiratory medicine·2006
Same journal

Respiratory syncytial virus bronchiolitis : current and future strategies for treatment and prophylaxis.

Treatments in respiratory medicine·2006
Same journal

Corticosteroid insensitivity in smokers with asthma : clinical evidence, mechanisms, and management.

Treatments in respiratory medicine·2006
Same journal

A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.

Treatments in respiratory medicine·2006
See all related articles

Area of Science:

  • Respiratory Medicine
  • Pharmacology
  • Pulmonary Disease

Background:

  • Ipratropium bromide is a key bronchodilator for COPD management.
  • Chlorofluorocarbon (CFC) propellants are being phased out globally.
  • Hydrofluoroalkane (HFA) propellants are replacing CFCs in metered-dose inhalers (MDIs).

Purpose of the Study:

  • To evaluate the efficacy and safety of a new hydrofluoroalkane (HFA)-propelled ipratropium bromide MDI.
  • To compare the HFA formulation with the previously used CFC-propelled ipratropium bromide MDI.
  • To support the use of ipratropium bromide HFA for maintenance treatment of COPD.

Main Methods:

  • A large, randomized, double-blind, placebo-controlled, 12-week trial.
  • An open-label, 1-year safety study.

Related Experiment Videos

  • Spirometric testing to measure bronchodilator efficacy.
  • Assessment of adverse events and tolerability profiles.

    • Main Results:

    • Ipratropium bromide HFA 42 mcg demonstrated comparable efficacy to ipratropium bromide CFC 42 mcg in spirometric testing.
    • Both formulations provided comparable bronchodilation in patients with stable COPD over a 1-year study.
    • Tolerability profiles were similar between ipratropium bromide HFA and CFC groups, with respiratory disorders being the most common adverse events.

    Conclusions:

    • Ipratropium bromide HFA is an effective and well-tolerated alternative to CFC-propelled ipratropium bromide for COPD.
    • The HFA formulation meets the need for a propellant-free metered-dose inhaler for ipratropium bromide.
    • This new formulation supports continued access to ipratropium bromide treatment for patients with chronic obstructive pulmonary disease.